Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

By A. Prahallad, Chong Sun, Sidong Huang, Federica Di Nicolantonio, R. Salazar, D. Zecchin, R. Beijersbergen, A. Bardelli, René Bernards. Nature, 2012

1,935 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/10564d8dc4a3ddb05a84b5a3ca8b7b622c5c17ea

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Carlos L. Arteaga
2. Myles A. Brown
3. X. S. Liu
4. F. Janku
5. Michael I. Love
6. Wei Li
7. E. Jeng
8. D. Hoon

In Oncology

1. Jean-Pierre Issa
2. Carlos L. Arteaga
3. Nicolas Stransky
4. Fortunato Ciardiello
5. J. Engelman

Citations in the corpus

• Systems biology approaches for advancing the discovery of effective drug combinations (2015, background): “In another study, Prahallad et al. used an RNAi screen to identify kinases whose knockdown synergized with BRAF (V600E) inhibition in colon tumors [69].”
• ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics (2014, background): “For example, in BRAF mutant CRC, BRAF inhibitors fail to inhibit ERK signaling in sustained fashion due to activation of EGFR which, in turn, reactivates ERK in the presence of the BRAF inhibitor (Corcoran et al., 2012; Prahallad et al., 2012).”
• MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens (2014, result): “Our finding is consistent with recent studies linking ectopic EGFR expression in melanoma cells to PLX resistance [14,28] and with the improved efficacy of BRAF and EGFR combination inhibition in”
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Also, BRAF V600E-mutated melanomas are sensitive to the BRAF-mutant inhibitor vemurafenib [69], but BRAF-mutated CRCs are not as sensitive [70, 71].”
• The Next-Generation Sequencing Revolution and Its Impact on Genomics (2013, neutral): “This phenomenon has mainly been studied at the protein level (Girotti et al., 2013; Prahallad et al., 2012) or by focused sequencing (Sequist et al., 2011).”
• Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (2015, background): “Preclinical studies since this clinical trial was first reported have added considerably to our understanding of MAPK inhibition and early reactivation of the pathway in CRC, with perhaps the most compelling reactivation being through feedback EGFR reactivation.(23,24) It has been proposed that EGFR”
• Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR (2015, background): “These genes include EGFR and BRAF, two known kinases that drive melanoma progression and PLX resistance [20, 21], and CRKL, a protein kinase that activates RAS and JUN pathway.”
• Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset (2015, neutral): “This particular group of CCLs is restricted to the skin lineage, a finding that is also observed in patients (19).”
• Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. (2019, background): “Arthralgia 23 (10) 0 41 (19) 2 (1) 1 (1) 0”